The product chosen as an example for this regulatory option is not in the current list of PRIME medicines: it is called MB-CART19.1 [23], it targets CD19, and has been used against an autoimmune disease known as Systemic Lupus Erythematosus (SLE) [24,25] in Germany. This evidence concerns the gene CD19 and systemic lupus erythematosus.